Semaglutide 2 mg lyophilized
all peptides ship in unlabeled vials, with color coded cap for batch identification
Semaglutide is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents. There have been no published reports of hepatotoxicity attributed to semaglutide therapy.
Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide.
The primary focus of GLP-1 research has been in the realm of diabetes treatment/prevention as well as appetite suppression. Secondary research focuses on the potential cardiovascular benefits of the peptide. More recent, and thus less robust, research focuses on the ability of GLP-1 to stave off neurodegenerative disease. Though this latter area of research is newest, it is also the fast-growing area of GLP-1 study now that the peptide has been revealed to slow or prevent the accumulation of amyloid beta plaques in the setting of Alzheimer’s disease.
Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.
THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. All product information available on this website is for educational purposes only.
|31436480||2020-01-01||Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist||Diabetes technology & therapeutics|
|31185157||2019-08-29||Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes||The New England journal of medicine|
|29915923||2018-12-01||Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist||Clinical pharmacokinetics|
|29756388||2018-09-01||Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis||Diabetes, obesity & metabolism|
|29766634||2018-09-01||Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials||Diabetes, obesity & metabolism|
|29205786||2018-04-01||Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment||Diabetes, obesity & metabolism|
|29049653||2017-10-17||Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial||JAMA|
|28266779||2017-09-01||Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity||Diabetes, obesity & metabolism|
|28323117||2017-06-15||Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species||European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences|
|26308095||2015-09-24||Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide||Journal of medicinal chemistry|
|24608440||2014-07-01||The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates||Diabetes|
|5316||1975-09-01||[Effect of electrolytes on the extraction of coniine, phenatin, cyclodol and tropacine by organic solvents]||Farmatsiia|